Midostaurine (Rydapt) dans le traitement de la mastocytose systémique

Détails

Fichiers
Generic Name:
Midostaurin
État du projet:
Terminé
Domaine thérapeutique:
Systemic Mastocytosis
Fabricant:
Novartis Canada
Brand Name:
Rydapt
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0193-000
Statut de l’AC au moment du dépôt:
Post AC
Strength:
25 mg
Tumour Type:
Autre
Indications:
Mastocytose systémique
Funding Request:
Dans le traitement de patients adultes atteints de mastocytose systémique grave (MSG), de mastocytose systémique associée au néoplasme hématologique (MS-ANH) ou de leucémie à mastocytes.
Sponsor:
Novartis Canada
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Ne pas rembourser
pERC Meeting:
Final Recommendation Issued:

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.